[The need for special caution in the treatment of spastic pyloric syndromes with central spasmolytics, with special reference to vasano].
D001533:Belladonna Alkaloids / Q000627:therapeutic use*; D002493:Central Nervous System Diseases; D002648:Child / Q000503:physiopathology; D006301:Health Services Needs and Demand; D006801:Humans; D007223:Infant / Q000503:physiopathology; D009128:Muscle Spasticity; D010276:Parasympatholytics; D011708:Pylorus / Q000503:physiopathology*; D013577:Syndrome
D001533:Belladonna Alkaloids; D010276:Parasympatholytics
BELLADONNA ALKALOIDS/therapeutic use; PYLOROSPASM/in infant and child
Uber die Notwendigkeit besonderer Vorsicht bei Behandlung spastischer Pylorussyndrome mit zentralwirksamen Spasmolytica (hier Vasano).